Open AccessEmploying bioactive compounds derived from Ipomoea obscura (L.) to evaluate potential inhibitor for SARS‐CoV‐2 main protease and ACE2 protein
Author(s) -
Poochi Saravana Prabha,
Easwaran Murugesh,
Balasubramanian Balamuralikrishnan,
Anbuselvam Mohan,
Meyyazhagan Arun,
Park Sungkwon,
Bhotla Haripriya Kuchi,
Anbuselvam Jeeva,
Arumugam Vijaya Anand,
Keshavarao Sasikala,
Kanniyappan Gopalakrishnan Velliyur,
Pappusamy Manikantan,
Kaul Tanushri
Publication year - 2020
Publication title -
food frontiers
Language(s) - English
Resource type - Journals
ISSN - 2643-8429
DOI - 10.1002/fft2.29
Subject(s) - protease , protease inhibitor (pharmacology) , covid-19 , virology , biology , chemistry , biochemistry , virus , enzyme , medicine , viral load , disease , pathology , antiretroviral therapy , infectious disease (medical specialty)
Angiotensin converting enzyme 2 (ACE2) and main protease (M Pro ) are significant target proteins, mainly involved in the attachment of viral genome to host cells and aid in replication of severe acute respiratory syndrome‐coronaviruses or SARS‐CoV genome. In the present study, we identified 11 potent bioactive compounds from ethanolic leaf extract of Ipomoea obscura (L.) by using GC‐MS analysis. These potential bioactive compounds were considered for molecular docking studies against ACE2 and M Pro target proteins to determine the antiviral effects against SARS‐COV. Results exhibits that among 11 compounds from I. obscura (L.), urso‐deoxycholic acid, demeclocycline, tetracycline, chlorotetracycline, and ethyl iso‐allocholate had potential viral inhibitory activity. Hence, the present findings suggested that chemical constitution present in I. obscura (L.) will address inhibition of corona viral replication in host cells.